MedDataX Logo

Caffeine Consumption and Cataract Prevention

NCT ID: NCT05194696

Last Updated: 2022-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

12000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2025-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of peroral caffeine consumption on the delay of cataract onset.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several experimental studies have shown that caffeine inhibits cataract development by scavenging reactive oxygen species. Evidence from epidemiological studies, however, is controversial. Varma et al., found that the incidence of cataract blindness in humans was significantly lower in groups consuming higher amounts of coffee in comparison to the groups with lower coffee intake. Moreover, Rautiainen et al. showed that the dietary total antioxidant capacity including coffee of middle-aged and elderly women was inversely associated with the risk of age-dependent cataract. Another population-based study involving the population residing in Beaver Dam, Wisconsin, did not find a meaningful association between 10-year cumulative incidence of cataract and the amount of caffeine intake.

Although cataracts can be surgically removed, barriers that prevent access to surgery are a problem in many countries. Moreover, no prophylactic treatments are currently available to prevent the onset of cataract. Yet estimates indicate that a delay of only 10 years in the onset of cataract could reduce the need for cataract surgery by as much as 50%.

The present study aims to investigate whether peroral caffeine consumption on a regular daily basis for a significant period of time and sufficient dose delays cataract development.

12000 eyes of 6000 patients will be included into this study. Patient will have to fill out a questionnaire for caffeine consumption habits during lifetime and risk factors for cataract development. Further, a complete ophthalmic examination, cataract grading, refraction, visual testing, and biometry will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cataract Caffeine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caffeine questionnaire

A questionnaire concerning caffeine habits will be handed out to the patients

Questionnaire

Intervention Type BEHAVIORAL

Patients have to answer a questionnaire about their caffeine consumption habits during lifetime

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

Patients have to answer a questionnaire about their caffeine consumption habits during lifetime

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age older than 21 years
* cataract

Exclusion Criteria

\- age younger than 21 years
Minimum Eligible Age

21 Years

Maximum Eligible Age

105 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vienna Institute for Research in Ocular Surgery

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prim. Prof. Dr. Oliver Findl, MBA

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Oliver Findl, MD

Role: PRINCIPAL_INVESTIGATOR

Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

Vienna, , Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Martin Kronschläger, PhD

Role: CONTACT

Phone: 01 91021

Email: [email protected]

Manuel Ruiss, MSc

Role: CONTACT

Phone: 01 91021

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Martin Kronschläger, PhD

Role: primary

Manuel Ruiss, MSc

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CaffQuest

Identifier Type: -

Identifier Source: org_study_id